-
Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline
Tuesday, April 13, 2021 - 12:03pm | 469Key recent clinical pipeline developments have prompted an analyst at Truist Securities to turn bullish on pharma giant Bristol-Myers Squibb Company (NYSE: BMY). The Bristol-Myers Squibb Analyst: Gregg Gilbert upgraded Bristol-Myers Squibb from Hold to Buy and increased the price target from $66...
-
How Valeant Finally Won Over A Longtime Bear
Monday, March 5, 2018 - 11:34am | 367Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell 20 percent after reporting in-line earnings results. But the very news that catalyzed a selloff was well-received by one longtime Valeant bear who transformed into a bull Monday. The Rating Deutsche Bank analyst Gregg Gilbert ...
-
Analyst Eats 'Some Humble Pie,' Says Teva Needs To Deliver On Greater Visibility In Coming Months
Friday, November 3, 2017 - 11:09am | 349Analysts at Deutsche Bank see a scenario in which Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock can move higher from its current levels but are simultaneously no longer recommending investors be buying the stock. The firm's Gregg Gilbert downgraded Teva's stock from Buy...
-
Zoetis Investors May Need Patience To See Bull Thesis Play Out
Wednesday, July 26, 2017 - 11:08am | 355After a more than 15-percent gain in Zoetis Inc (NYSE: ZTS) since the start of 2017, analysts at Deutsche Bank see little incremental upside in the near-term. Gregg Gilbert downgraded Zoetis' stock from Buy to Hold with an unchanged $65 price target as it has handily outperformed the S&P...
-
Akorn Take-Out Chatter Supported By Trend Of Consolidation In Generic Drug Companies
Monday, April 10, 2017 - 9:46am | 364A Bloomberg article Friday suggested that the European company Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS) is considering a bid for Akorn, Inc. (NASDAQ: AKRX). While there is lack of certainty regarding whether such a deal would materialize and at what price, “we continue to believe...
-
Valeant's Refinancing Explained
Wednesday, March 8, 2017 - 6:29pm | 342Gregg Gilbert of Deutsche Bank reaffirmed his Hold rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and made some preliminary assumptions for the company’s planned debt refinancing. The refinancing could potentially extend some near-term maturities, reduce floating-rate debt, and...
-
More Pros Than Cons Investing In Impax Right Now
Wednesday, March 8, 2017 - 9:46am | 295A Reuters article, published on March 7 suggested that Impax Laboratories Inc (NASDAQ: IPXL) hired an investment bank to help it explore strategic options, which could include an acquisition or sale of the company. “We believe patient investors could be rewarded if business trends improve, or...
-
Does Reward Potential Still Outweigh The Risk In Akorn Shares?
Monday, March 6, 2017 - 2:25pm | 296Deutsche Bank downgraded Akorn, Inc. (NASDAQ: AKRX) to Hold from Buy as the stock has recovered since the post-third quarter correction. According to Deutsche Bank, further upside will depend on “hard-to-call dynamics of new product approvals vs. base business erosion.” Akorn has a...
-
Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers
Wednesday, February 15, 2017 - 3:26pm | 558Gregg Gilbert of Deutsche Bank would be surprised if Pfizer Inc. (NYSE: PFE) approaches Bristol-Myers Squibb Co (NYSE: BMY) with a takeover bid at this stage. The brokerage issued the comment after Street Insider said Roche Holding Ltd. (ADR) (OTC: RHHBY), Novartis AG (ADR) (NYSE: NVS)and Pfizer...
-
What The Copaxone Court Ruling Means For Teva Pharmaceuticals
Tuesday, January 31, 2017 - 12:35pm | 285“The district court ruled against Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) in the Copaxone 40mg patent case, invalidating each of the four patents in the case,” Deutsche Bank’s Gregg Gilbert said in a note, while maintaining a Buy rating on the company, with a price...
-
Amid Exec Departure, Teva's 2017 Outlook Now More Important Than Ever
Tuesday, December 6, 2016 - 12:34pm | 316Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced that Dipankar Bhattacharjee, the CEO of Teva generics Europe, has been appointed as the new head of global generics. Deutsche Bank’s Gregg Gilbert maintains a Buy rating on the company, with a price target of $54. Executive...
-
Deutsche Tweaking Its Mylan View Following CEO's Congressional Testimony
Friday, September 23, 2016 - 3:04pm | 355Deutsche Bank trimmed its estimates and target price on Mylan NV (NASDAQ: MYL) shares following CEO Heather Bresch's Congressional testimony over the price hike of EpiPen allergy shots. Mylan raised the price of EpiPen, which accounts for 40 percent of its operating profits, to $600 for a two-pack...
-
Recent Patent Ruling A Positive For Pfizer
Thursday, August 18, 2016 - 2:26pm | 331A Federal District Court in Massachusetts recently issued a patent ruling that is "favorable" for Pfizer Inc. (NYSE: PFE), according to Gregg Gilbert of Deutsche Bank. As noted by Gilbert, the District Court ruled in favor of Pfizer and Celltrion and said that Johnson & Johnson (NYSE: JNJ)'s...
-
Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report
Thursday, August 11, 2016 - 3:04pm | 259Deutsche Bank maintained its Buy rating on Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) despite the company's second quarter earnings miss. "While management's mention of a slowdown in the diagnosis of narcolepsy and continued payer hurdles may create some concern that...
-
Deutsche Thinks Perrigo's Lowered Expectations Are Beatable
Thursday, August 11, 2016 - 2:12pm | 273Deutsche Bank maintained its Buy rating on Perrigo Company plc Ordinary Shares (NYSE: PRGO) and said the company's lowered 2016 outlook is "meetable/beatable." The Dublin-based company now expects 2016 earnings in the range of $6.85 to $7.15 per share, down from prior guidance of...